49Z Stock Overview
Operates as a bioconvergence company in North America, Europe, Asia, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
BICO Group AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr3.85 |
52 Week High | kr6.35 |
52 Week Low | kr2.04 |
Beta | 2.31 |
11 Month Change | -1.08% |
3 Month Change | -0.54% |
1 Year Change | 29.80% |
33 Year Change | -90.84% |
5 Year Change | n/a |
Change since IPO | -60.31% |
Recent News & Updates
Recent updates
Shareholder Returns
49Z | DE Life Sciences | DE Market | |
---|---|---|---|
7D | -1.0% | -2.3% | 0.9% |
1Y | 29.8% | -14.3% | 4.2% |
Return vs Industry: 49Z exceeded the German Life Sciences industry which returned -14.3% over the past year.
Return vs Market: 49Z exceeded the German Market which returned 4.2% over the past year.
Price Volatility
49Z volatility | |
---|---|
49Z Average Weekly Movement | n/a |
Life Sciences Industry Average Movement | 6.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 49Z has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 49Z's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 837 | Maria Forss | www.bico.com |
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
BICO Group AB (publ) Fundamentals Summary
49Z fundamental statistics | |
---|---|
Market cap | €276.77m |
Earnings (TTM) | -€146.60m |
Revenue (TTM) | €215.67m |
1.3x
P/S Ratio-1.9x
P/E RatioIs 49Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
49Z income statement (TTM) | |
---|---|
Revenue | kr2.43b |
Cost of Revenue | kr716.50m |
Gross Profit | kr1.71b |
Other Expenses | kr3.36b |
Earnings | -kr1.65b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
Earnings per share (EPS) | -23.37 |
Gross Margin | 70.47% |
Net Profit Margin | -67.97% |
Debt/Equity Ratio | 47.1% |
How did 49Z perform over the long term?
See historical performance and comparison